Drug Profile
Research programme: small molecule therapeutics - Exscientia/GlaxoSmithKline
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Exscientia; GlaxoSmithKline
- Developer Exscientia; GSK
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Chronic-obstructive-pulmonary-disease in United Kingdom
- 02 Jul 2017 Exscientia and GlaxoSmithKline enter into a collaboration to discover and develop small molecule therapeutics for multiple therapeutic areas
- 02 Jul 2017 Early research in Undefined indication in United Kingdom (unspecified route)